

Table 4.26

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	280,343	99.4%	227,311	99.4%	29,434	99.3%	20,070	99.3%	1,070	99.0%	27,008	99.2%
Epidermoid carcinoma ^d (8051-8131)	148	0.1%	121	0.1%	19	0.1%	-	-	-	-	18	0.1%
Adenocarcinoma ^e	274,394	97.3%	222,769	97.5%	28,468	96.0%	19,726	97.6%	1,041	96.3%	26,369	96.8%
Adenocarcinoma, NOS (8140)	2,324	0.8%	1,854	0.8%	284	1.0%	136	0.7%	-	-	239	0.9%
Infiltrating duct carcinoma (8500)	203,964	72.3%	163,512	71.5%	22,253	75.1%	15,655	77.4%	807	74.7%	19,880	73.0%
Lobular carcinoma, NOS (8520)	24,403	8.7%	21,118	9.2%	1,967	6.6%	1,038	5.1%	68	6.3%	1,940	7.1%
Inflammatory adenocarcinoma (8530)	1,233	0.4%	957	0.4%	213	0.7%	52	0.3%	-	-	164	0.6%
Infiltrating duct mixed and infiltrating lobular mixed (8522-8524)	27,590	9.8%	23,405	10.2%	2,211	7.5%	1,637	8.1%	97	9.0%	2,747	10.1%
Mucinous adenocarcinoma (8480,8482)	5,969	2.1%	4,750	2.1%	582	2.0%	551	2.7%	22	2.0%	510	1.9%
Mucin-producing adenocarcinoma (8481)	88	0.0%	68	0.0%	-	-	-	-	-	-	-	-
Tubular adenocarcinoma (8211)	2,315	0.8%	2,080	0.9%	123	0.4%	94	0.5%	-	-	165	0.6%
Papillary adenocarcinoma (8050,8260,8503,8504)	1,621	0.6%	1,149	0.5%	272	0.9%	177	0.9%	-	-	177	0.7%
Paget disease (8540-8543)	1,430	0.5%	1,149	0.5%	141	0.5%	117	0.6%	-	-	173	0.6%
Other adenocarcinomas ^f	3,457	1.2%	2,727	1.2%	409	1.4%	264	1.3%	-	-	364	1.3%
Other specific carcinomas ^g	2,485	0.9%	1,842	0.8%	479	1.6%	137	0.7%	-	-	299	1.1%
Medullary adenocarcinoma (8510-8513)	1,022	0.4%	702	0.3%	251	0.8%	59	0.3%	-	-	154	0.6%
Other ^h	1,463	0.5%	1,140	0.5%	228	0.8%	78	0.4%	-	-	145	0.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	3,316	1.2%	2,579	1.1%	468	1.6%	201	1.0%	17	1.6%	322	1.2%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Other adenocarcinomas include histologies 8141-8147, 8160-8162, 8180-8210, 8212-8221, 8250-8259, 8261-8479, 8483-8499, 8501-8502, 8505-8507, 8514, 8521, 8525-8529, 8531-8539, 8544-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.26 - continued

Cancer of the Female Breast (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 9040-9044,9120-9136, 9150-9252,9370-9373, 9540-9582)	310	0.1%	246	0.1%	34	0.1%	26	0.1%	-	-	28	0.1%
Hemangiosarcomas (9120-9126,9170)	154	0.1%	135	0.1%	-	-	-	-	-	-	17	0.1%
Other sarcomas ^d	156	0.1%	111	0.0%	27	0.1%	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	747	0.3%	558	0.2%	93	0.3%	85	0.4%	-	-	136	0.5%
Phyllodes tumor, malignant (9020)	617	0.2%	464	0.2%	65	0.2%	80	0.4%	-	-	115	0.4%
Other ^e	130	0.0%	94	0.0%	28	0.1%	-	-	-	-	21	0.1%
Unspecified (8000-8005)	604	0.2%	456	0.2%	78	0.3%	33	0.2%	-	-	60	0.2%
Total ^f	282,004	100.0%	228,571	100.0%	29,639	100.0%	20,214	100.0%	1,081	100.0%	27,232	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Other sarcomas include histologies 8680-8713, 8800-8921, 9040-9044, 9127-9136, 9150-9169, 9171-9252, 9370-9373, 9540-9582.

^e Other includes histologies 8720-8790, 8930-8936, 8950-9019, 9021-9030, 9060-9110, 9260-9365, 9380-9539.

^f Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 4.27

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	71,958	99.7%	57,078	99.7%	7,346	99.6%	6,471	99.9%	205	100.0%	6,352	99.8%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^f	60,766	84.2%	47,669	83.3%	6,423	87.1%	5,861	90.5%	171	83.4%	5,405	84.9%
Cribiform carcinoma <i>in situ</i> (8201/2)	5,963	8.3%	4,606	8.0%	629	8.5%	619	9.6%	25	12.2%	562	8.8%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	4,485	6.2%	3,651	6.4%	371	5.0%	410	6.3%	-	-	366	5.8%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	23,138	32.1%	18,424	32.2%	2,486	33.7%	1,920	29.6%	65	31.7%	1,962	30.8%
Comedocarcinoma <i>in situ</i> (8501/2)	5,406	7.5%	4,268	7.5%	570	7.7%	493	7.6%	19	9.3%	488	7.7%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,206	1.7%	832	1.5%	211	2.9%	134	2.1%	-	-	121	1.9%
Noninfiltrating intracystic carcinoma(8504/2)	312	0.4%	208	0.4%	44	0.6%	55	0.8%	-	-	31	0.5%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,529	2.1%	1,227	2.1%	177	2.4%	108	1.7%	-	-	128	2.0%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	18,543	25.7%	14,306	25.0%	1,921	26.0%	2,101	32.4%	36	17.6%	1,728	27.2%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	8,296	11.5%	7,062	12.3%	650	8.8%	378	5.8%	23	11.2%	687	10.8%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	8,269	11.5%	7,039	12.3%	646	8.8%	378	5.8%	23	11.2%	687	10.8%
Lobular CIS ^f with other CIS ^f (8524/2)	26	0.0%	23	0.0%	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	2,430	3.4%	1,987	3.5%	229	3.1%	178	2.7%	-	-	218	3.4%
Other adenocarcinomas ^g	458	0.6%	352	0.6%	44	0.6%	54	0.8%	-	-	42	0.7%
Other <i>in situ</i> histologies ^h	188	0.3%	149	0.3%	29	0.4%	-	-	-	-	-	-
Total	72,146	100.0%	57,227	100.0%	7,375	100.0%	6,476	100.0%	205	100.0%	6,363	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^f CIS = Carcinoma *in situ*.

^g Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

^h Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 5.16

Cancer of the Cervix Uteri (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	16,669	98.2%	12,558	98.3%	2,331	97.7%	1,425	98.5%	115	98.3%	3,735	98.5%
Epidermoid carcinoma ^d (8050-8131)	11,319	66.7%	8,281	64.8%	1,860	78.0%	941	65.0%	79	67.5%	2,601	68.6%
Squamous cell carcinoma (8070)	7,668	45.2%	5,535	43.3%	1,364	57.2%	610	42.2%	53	45.3%	1,577	41.6%
Squamous cell, keratinizing (8071)	1,214	7.2%	887	6.9%	200	8.4%	106	7.3%	-	-	330	8.7%
Squamous cell, non-keratinizing (8072)	1,525	9.0%	1,160	9.1%	197	8.3%	141	9.7%	-	-	445	11.7%
Squamous cell, Microinvasive (8076)	653	3.8%	508	4.0%	62	2.6%	57	3.9%	-	-	187	4.9%
Other (8050-8069, 8073-8075,8077-8131)	259	1.5%	191	1.5%	37	1.6%	27	1.9%	-	-	62	1.6%
Adenocarcinoma ^e	4,634	27.3%	3,765	29.5%	349	14.6%	430	29.7%	27	23.1%	971	25.6%
Adenocarcinoma, NOS (8140)	2,456	14.5%	2,011	15.7%	178	7.5%	219	15.1%	-	-	515	13.6%
Adenosquamous (8560,8570)	658	3.9%	519	4.1%	64	2.7%	63	4.4%	-	-	159	4.2%
Other adenocarcinomas ^f	1,520	9.0%	1,235	9.7%	107	4.5%	148	10.2%	-	-	297	7.8%
Other specific carcinomas ^g	235	1.4%	184	1.4%	29	1.2%	18	1.2%	-	-	54	1.4%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	481	2.8%	328	2.6%	93	3.9%	36	2.5%	-	-	109	2.9%
Sarcoma ^h	69	0.4%	53	0.4%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-9030,9060-9110, 9260-9365,9380-9539)	152	0.9%	104	0.8%	29	1.2%	16	1.1%	-	-	23	0.6%
Unspecified (8000-8005)	88	0.5%	66	0.5%	-	-	-	-	-	-	17	0.4%
Total	16,978	100.0%	12,781	100.0%	2,385	100.0%	1,447	100.0%	117	100.0%	3,790	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinomas include histologies 8141-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8571-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8175,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Sarcoma includes histologies 8680-8713,8800-8921,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	183,663	99.5%	145,685	99.5%	21,531	99.5%	13,667	99.5%	871	99.1%	17,382	99.5%
Epidermoid carcinoma ^d (8051-8131)	1,023	0.6%	868	0.6%	119	0.5%	16	0.1%	-	-	78	0.4%
Squamous cell carcinoma (8070-8078,8083-8084)	967	0.5%	820	0.6%	113	0.5%	16	0.1%	-	-	72	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8520-8551,8560, 8570-8574,8576,8940-8941)	172,934	93.7%	138,269	94.4%	19,669	90.9%	12,709	92.6%	807	91.8%	16,209	92.7%
Adenocarcinoma, NOS (8140)	118,914	64.4%	94,737	64.7%	13,694	63.3%	9,080	66.1%	596	67.8%	11,117	63.6%
Adenocarcinoma in adenomatous polyp (8210)	14,652	7.9%	11,646	8.0%	1,493	6.9%	1,183	8.6%	69	7.8%	1,314	7.5%
Adenocarcinoma in villous adenoma (8261)	5,108	2.8%	4,135	2.8%	542	2.5%	359	2.6%	23	2.6%	593	3.4%
Mucinous adenocarcinoma (8470-8473,8480,8482)	12,170	6.6%	10,110	6.9%	1,266	5.8%	692	5.0%	40	4.6%	1,191	6.8%
Mucin-producing adenocarcinoma (8481)	2,505	1.4%	2,039	1.4%	344	1.6%	110	0.8%	-	-	218	1.2%
Signet ring adenocarcinoma (8490)	2,038	1.1%	1,697	1.2%	171	0.8%	153	1.1%	-	-	201	1.2%
Other adenocarcinomas ^e	17,547	9.5%	13,905	9.5%	2,159	10.0%	1,132	8.2%	68	7.7%	1,575	9.0%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	8,042	4.4%	5,255	3.6%	1,538	7.1%	820	6.0%	42	4.8%	942	5.4%
Neuroendocrine carcinoid (8240-8245)	6,545	3.5%	4,049	2.8%	1,368	6.3%	723	5.3%	35	4.0%	799	4.6%
Other ^f	1,497	0.8%	1,206	0.8%	170	0.8%	97	0.7%	-	-	143	0.8%
Unspecified, Carcinoma, NOS (8010-8011, 8020-8022)	1,664	0.9%	1,293	0.9%	205	0.9%	122	0.9%	20	2.3%	153	0.9%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Includes histologies 8050, 8141-8147, 8160-8162, 8180-8204, 8211-8221, 8250-8260, 8262-8264, 8270-8463, 8500-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^f Includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8231, 8246-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 6.29 - continued

Cancer of the Colon And Rectum (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	104	0.1%	87	0.1%	-	-	-	-	-	-	18	0.1%
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	257	0.1%	183	0.1%	40	0.2%	32	0.2%	-	-	25	0.1%
Unspecified (8000-8005)	564	0.3%	457	0.3%	65	0.3%	26	0.2%	-	-	52	0.3%
Total ^d	184,588	100.0%	146,412	100.0%	21,646	100.0%	13,731	100.0%	879	100.0%	17,477	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 8.22

Cancer of the Esophagus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	18,073	99.1%	15,067	99.1%	2,013	99.2%	793	99.0%	84	100.0%	1,240	99.0%
Epidermoid carcinoma ^d (8051-8131)	6,244	34.2%	3,984	26.2%	1,635	80.6%	555	69.3%	33	39.3%	509	40.7%
Squamous cell carcinoma (8070-8078, 8083-8084)	6,230	34.2%	3,973	26.1%	1,632	80.4%	555	69.3%	33	39.3%	508	40.6%
Adenocarcinoma ^e	10,927	59.9%	10,323	67.9%	298	14.7%	197	24.6%	45	53.6%	662	52.9%
Other specific carcinomas ^f	294	1.6%	246	1.6%	31	1.5%	-	-	-	-	19	1.5%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	608	3.3%	514	3.4%	49	2.4%	31	3.9%	-	-	50	4.0%
Other specific types ^g	46	0.3%	35	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	116	0.6%	100	0.7%	-	-	-	-	-	-	-	-
Total	18,235	100.0%	15,202	100.0%	2,029	100.0%	801	100.0%	84	100.0%	1,252	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma is defined as histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas is defined as histologies 8012-8015, 8030-8046, 8150-8155, 8170-8175, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^h Other specific types includes sarcomas and other soft tissue tumors.

ⁱ Other specific types is defined as histologies 8680-8713, 8720-8790, 8800-8921, 8930-8936, 8950-9030, 9040-9044, 9060-9110, 9120-9136, 9150-9252, 9260-9365, 9370-9373, 9380-9539, 9540-9582.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 14.22

Cancer of the Liver and Intrahepatic Bile Duct (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma (8010-8576)	21,110	97.3%	14,834	96.9%	2,700	98.5%	3,245	97.9%	180	97.3%	3,428	95.5%
Hepatocellular carcinoma ^d (8170-8175)	16,478	75.9%	11,258	73.6%	2,286	83.4%	2,672	80.6%	142	76.8%	2,756	76.8%
Cholangiocarcinoma (8032-8033,8070-8071, 8140-8141,8160,8260, 8480-8481,8490,8560)	3,628	16.7%	2,862	18.7%	296	10.8%	420	12.7%	29	15.7%	513	14.3%
Other carcinoma ^e	1,004	4.6%	714	4.7%	118	4.3%	153	4.6%	-	-	159	4.4%
Other specific carcinoma ^f	625	2.9%	457	3.0%	61	2.2%	99	3.0%	-	-	102	2.8%
Unspecified, Carcinoma, NOS (8010,8020-8022,8031, 8046,8050)	379	1.7%	257	1.7%	57	2.1%	54	1.6%	-	-	57	1.6%
Hepatoblastoma (8970)	196	0.9%	155	1.0%	-	-	23	0.7%	-	-	77	2.1%
Sarcoma ^g	188	0.9%	152	1.0%	17	0.6%	16	0.5%	-	-	33	0.9%
Hemangiosarcoma (9120)	67	0.3%	57	0.4%	-	-	-	-	-	-	-	-
Other sarcomas ^h	121	0.6%	95	0.6%	-	-	-	-	-	-	21	0.6%
Other specific types (8720,8980,8991,9061, 9064,9070-9071,9080, 9100)	45	0.2%	30	0.2%	-	-	-	-	-	-	-	-
Unspecified (8000-8004)	162	0.7%	130	0.8%	-	-	22	0.7%	-	-	36	1.0%
Total ^d	21,702	100.0%	15,302	100.0%	2,741	100.0%	3,315	100.0%	185	100.0%	3,588	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percentages may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma arising from liver parenchyma are referred to as hepatocellular carcinoma.

^f Other carcinoma include histologies 8010, 8012-8013, 8020-8022, 8031, 8035, 8041-8042, 8046, 8050, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^g Other specific carcinoma include histologies 8012-8013, 8035, 8041-8042, 8124, 8142, 8154, 8161-8162, 8180, 8190, 8211, 8240, 8246, 8249, 8255, 8290, 8310, 8323, 8337, 8440, 8450, 8453, 8470-8471, 8500, 8503, 8510, 8521, 8550, 8574, 8576.

^h Sarcoma includes histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9120, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

ⁱ Other sarcomas include histologies 8800-8806, 8810, 8815, 8830, 8850, 8852, 8854, 8890-8891, 8894-8896, 8900, 8910, 8920, 8935-8936, 8940, 8963, 8990, 9040-9041, 9044, 9124, 9130, 9133, 9150, 9180, 9220, 9260, 9364, 9473, 9500, 9540, 9560, 9581.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.28

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	224,350	98.9%	186,083	98.9%	24,620	98.9%	12,109	98.8%	729	97.9%	11,972	98.1%
Small cell (8041-8045)	30,845	13.6%	27,025	14.4%	2,626	10.5%	968	7.9%	140	18.8%	1,436	11.8%
Non-small cell ^d	193,505	85.3%	159,058	84.5%	21,994	88.3%	11,141	90.9%	589	79.1%	10,536	86.3%
Squamous and transitional cell ^e	48,561	21.4%	40,634	21.6%	5,732	23.0%	1,851	15.1%	178	23.9%	2,201	18.0%
Adenocarcinoma ^f	92,669	40.8%	75,509	40.1%	9,903	39.8%	6,698	54.7%	216	29.0%	5,366	44.0%
Large cell (8011-8015)	5,890	2.6%	4,817	2.6%	811	3.3%	223	1.8%	20	2.7%	280	2.3%
Other non-small cell ^g	46,385	20.4%	38,098	20.2%	5,548	22.3%	2,369	19.3%	175	23.5%	2,689	22.0%
Sarcoma ^h	422	0.2%	344	0.2%	43	0.2%	23	0.2%	-	-	47	0.4%
Other specified types ⁱ	187	0.1%	154	0.1%	24	0.1%	-	-	-	-	23	0.2%
Unspecified (8000-8005)	1,932	0.9%	1,581	0.8%	218	0.9%	112	0.9%	-	-	163	1.3%
Total	226,891	100.0%	188,162	100.0%	24,905	100.0%	12,253	100.0%	745	100.0%	12,205	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^e Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^f Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^g Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.29

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Males by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	119,723	98.8%	97,995	98.8%	13,938	98.9%	6,959	98.7%	379	97.9%	6,382	98.2%
Small cell (8041-8045)	15,507	12.8%	13,407	13.5%	1,346	9.6%	651	9.2%	63	16.3%	777	12.0%
Non-small cell ^d	104,216	86.0%	84,588	85.3%	12,592	89.3%	6,308	89.5%	316	81.7%	5,605	86.2%
Squamous and transitional cell ^e	30,691	25.3%	25,394	25.6%	3,703	26.3%	1,362	19.3%	106	27.4%	1,420	21.8%
Adenocarcinoma ^f	45,076	37.2%	36,263	36.6%	5,200	36.9%	3,341	47.4%	100	25.8%	2,545	39.1%
Large cell (8011-8015)	3,357	2.8%	2,719	2.7%	473	3.4%	144	2.0%	-	-	168	2.6%
Other non-small cell ^g	25,092	20.7%	20,212	20.4%	3,216	22.8%	1,461	20.7%	99	25.6%	1,472	22.6%
Sarcoma ^h	229	0.2%	189	0.2%	21	0.1%	-	-	-	-	23	0.4%
Other specified types ⁱ	111	0.1%	94	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	1,065	0.9%	858	0.9%	124	0.9%	71	1.0%	-	-	82	1.3%
Total	121,128	100.0%	99,136	100.0%	14,093	100.0%	7,049	100.0%	387	100.0%	6,501	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^g Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^h Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

ⁱ Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 15.30

Cancer of the Lung and Bronchus (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	104,627	98.9%	88,088	98.9%	10,682	98.8%	5,150	99.0%	350	97.8%	5,590	98.0%
Small cell (8041-8045)	15,338	14.5%	13,618	15.3%	1,280	11.8%	317	6.1%	77	21.5%	659	11.6%
Non-small cell ^d	89,289	84.4%	74,470	83.6%	9,402	87.0%	4,833	92.9%	273	76.3%	4,931	86.4%
Squamous and transitional cell ^e	17,870	16.9%	15,240	17.1%	2,029	18.8%	489	9.4%	72	20.1%	781	13.7%
Adenocarcinoma ^f	47,593	45.0%	39,246	44.1%	4,703	43.5%	3,357	64.5%	116	32.4%	2,821	49.5%
Large cell (8011-8015)	2,533	2.4%	2,098	2.4%	338	3.1%	79	1.5%	-	-	112	2.0%
Other non-small cell ^g	21,293	20.1%	17,886	20.1%	2,332	21.6%	908	17.4%	76	21.2%	1,217	21.3%
Sarcoma ^h	193	0.2%	155	0.2%	22	0.2%	-	-	-	-	24	0.4%
Other specified types ⁱ	76	0.1%	60	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	867	0.8%	723	0.8%	94	0.9%	41	0.8%	-	-	81	1.4%
Total	105,763	100.0%	89,026	100.0%	10,812	100.0%	5,204	100.0%	358	100.0%	5,704	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Non-small cell includes histologies 8010-8015, 8020-8022, 8030-8040, 8046, 8050-8052, 8070-8084, 8090-8110, 8120-8131, 8140-8156, 8160-8162, 8170-8175, 8180, 8190-8221, 8230-8231, 8240-8263, 8270-8280, 8290-8337, 8340-8347, 8350-8390, 8400-8562, 8570-8576, 8580-8671, 8940-8941.

^f Squamous and transitional cell includes histologies 8051-8052, 8070-8084, 8120-8131.

^g Adenocarcinoma includes histologies 8050, 8140-8149, 8160-8162, 8190-8221, 8250-8263, 8270-8280, 8290-8337, 8350-8390, 8400-8560, 8570-8576, 8940-8941.

^h Other non-small cell includes large cell carcinoma, NOS, other specified carcinomas, and unspecified carcinomas.

ⁱ Other non-small cell is defined as histologies 8010, 8020-8022, 8030-8040, 8046, 8090-8110, 8150-8156, 8170-8175, 8180, 8230-8231, 8240-8249, 8340-8347, 8561-8562, 8580-8671.

^h Sarcoma includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types includes melanomas and is defined as histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	38,863	83.7%	2,700	94.6%	13,230	96.9%	1,156	21.8%	2,381	95.5%
Squamous cell carcinoma (8070-8078,8083-8084)	37,865	81.5%	2,597	91.0%	13,016	95.3%	1,101	20.7%	2,357	94.5%
Adenocarcinoma ^c	4,916	10.6%	115	4.0%	226	1.7%	3,290	62.0%	87	3.5%
Other specific carcinomas ^d	521	1.1%	-	-	40	0.3%	288	5.4%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,621	3.5%	-	-	101	0.7%	380	7.2%	-	-
Sarcoma and soft tissue ^e	167	0.4%	-	-	20	0.1%	39	0.7%	-	-
Other specific types ^f	212	0.5%	-	-	-	-	91	1.7%	-	-
Unspecified (8000-8005)	152	0.3%	-	-	25	0.2%	63	1.2%	-	-
Total	46,452	100.0%	2,855	100.0%	13,652	100.0%	5,307	100.0%	2,493	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	5,070	80.3%	1,700	62.2%	9,299	97.1%	2,666	96.4%	661	87.8%
Squamous cell carcinoma (8070-8078,8083-8084)	4,814	76.3%	1,506	55.1%	9,179	95.8%	2,641	95.5%	654	86.9%
Adenocarcinoma ^c	1,003	15.9%	89	3.3%	67	0.7%	22	0.8%	17	2.3%
Other specific carcinomas ^d	42	0.7%	54	2.0%	43	0.4%	23	0.8%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	64	1.0%	827	30.2%	140	1.5%	42	1.5%	41	5.4%
Sarcoma and soft tissue ^e	35	0.6%	40	1.5%	-	-	-	-	-	-
Other specific types ^f	79	1.3%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	18	0.3%	-	-	17	0.2%	-	-	-	-
Total	6,311	100.0%	2,735	100.0%	9,581	100.0%	2,765	100.0%	753	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	24,642	91.9%	20,746	92.4%	1,844	88.7%	1,764	90.1%	121	93.1%	2,792	87.8%
Epidermoid carcinoma ^d (8051-8131)	210	0.8%	166	0.7%	18	0.9%	21	1.1%	-	-	34	1.1%
Adenocarcinoma ^e	22,543	84.1%	19,057	84.8%	1,597	76.9%	1,629	83.2%	109	83.8%	2,511	78.9%
Adenocarcinoma, NOS (8140)	3,456	12.9%	2,841	12.6%	393	18.9%	190	9.7%	-	-	351	11.0%
Papillary adenocarcinoma, NOS (8050,8260)	445	1.7%	385	1.7%	35	1.7%	18	0.9%	-	-	50	1.6%
Clear cell adenocarcinoma (8310,9110)	1,362	5.1%	1,055	4.7%	50	2.4%	246	12.6%	-	-	132	4.1%
Endometrioid carcinoma (8380-8383,8570)	2,596	9.7%	2,201	9.8%	121	5.8%	233	11.9%	-	-	334	10.5%
Cystadenocarcinoma, NOS (8440,8450)	132	0.5%	106	0.5%	16	0.8%	-	-	-	-	18	0.6%
Serous cystadenocarcinoma (8441)	4,945	18.4%	4,236	18.9%	326	15.7%	311	15.9%	33	25.4%	515	16.2%
Papillary serous cystadenocarcinoma (8460-8462)	6,819	25.4%	5,925	26.4%	475	22.9%	361	18.4%	33	25.4%	731	23.0%
Mucinous cystadenocarcinoma (8470-8473)	465	1.7%	390	1.7%	28	1.3%	36	1.8%	-	-	82	2.6%
Mucinous adenocarcinoma (8480,8482)	929	3.5%	740	3.3%	83	4.0%	97	5.0%	-	-	127	4.0%
Mucin-producing adenocarcinoma(8481)	63	0.2%	54	0.2%	-	-	-	-	-	-	-	-
Other adenocarcinoma ^f	1,331	5.0%	1,124	5.0%	63	3.0%	127	6.5%	-	-	160	5.0%
Other specific carcinomas ^g	614	2.3%	460	2.0%	113	5.4%	33	1.7%	-	-	90	2.8%
Stromal cell tumor (8620-8631,8650)	391	1.5%	277	1.2%	86	4.1%	21	1.1%	-	-	56	1.8%
Other ^h	223	0.8%	183	0.8%	27	1.3%	-	-	-	-	34	1.1%
Unspecified, Carcinoma, NOS (8010,8020-8022)	1,275	4.8%	1,063	4.7%	116	5.6%	81	4.1%	-	-	157	4.9%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).
Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941,9110.

^g Other adenocarcinoma includes histologies 8141-8147,8160-8162,8180-8221,8250-8259,8261-8309,8311-8379,8384-8439,8442-8449,8451-8459,8463-8469,8474-8479,8483-8507,8514,8520-8551,8560,8571-8574,8576,8940-8941.

^h Other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Other subgroup of other specific carcinomas includes histologies 8011-8015,8030-8046,8150-8155,8170-8175,8230-8231,8247-8249,8508,8510-8513,8561-8562,8575,8580-8619,8632-8649,8651-8671.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 21.16 - continued

Cancer of the Ovary (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9141-9340, 9540-9582)	95	0.4%	69	0.3%	-	-	-	-	-	-	19	0.6%
Other specific types (8240-8246,8720-8790, 8930-8936,8950-8983, 9000-9030,9060-9105, 9350-9364,9380-9513, 9530-9539)	1,809	6.7%	1,425	6.3%	194	9.3%	165	8.4%	-	-	339	10.7%
Mullerian mixed tumor (8950-8951,8980)	770	2.9%	659	2.9%	63	3.0%	42	2.1%	-	-	65	2.0%
Teratoma, malignant (9080-9085,9102)	392	1.5%	281	1.3%	51	2.5%	52	2.7%	-	-	129	4.1%
Other	647	2.4%	485	2.2%	80	3.8%	71	3.6%	-	-	145	4.6%
Unspecified (8000-8005)	269	1.0%	221	1.0%	25	1.2%	17	0.9%	-	-	31	1.0%
Total ^d	26,815	100.0%	22,461	100.0%	2,078	100.0%	1,957	100.0%	130	100.0%	3,181	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 22.22

Cancer of the Pancreas (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	39,819	97.9%	32,058	97.9%	4,785	97.9%	2,630	97.9%	172	97.7%	3,819	97.4%
Epidermoid carcinoma ^d (8051-8131)	81	0.2%	63	0.2%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	34,978	86.0%	28,216	86.2%	4,152	85.0%	2,314	86.1%	149	84.7%	3,331	85.0%
Adenocarcinoma, NOS (8140)	28,419	69.9%	22,911	70.0%	3,441	70.4%	1,814	67.5%	128	72.7%	2,731	69.7%
Papillary adenocarcinoma, NOS (8260)	57	0.1%	45	0.1%	-	-	-	-	-	-	-	-
Mucinous adenocarcinoma (8480,8482)	1,085	2.7%	888	2.7%	121	2.5%	69	2.6%	-	-	99	2.5%
Mucin-producing adenocarcinoma (8481)	499	1.2%	407	1.2%	66	1.4%	24	0.9%	-	-	44	1.1%
Infiltrating duct carcinoma (8500-8503,8507,8514)	3,883	9.5%	3,136	9.6%	405	8.3%	320	11.9%	-	-	314	8.0%
Other adenocarcinoma ^f	1,035	2.5%	829	2.5%	115	2.4%	81	3.0%	-	-	131	3.3%
Other specific carcinomas ^g	2,498	6.1%	2,025	6.2%	296	6.1%	153	5.7%	-	-	247	6.3%
Islet cell carcinoma (8150-8155)	398	1.0%	334	1.0%	40	0.8%	21	0.8%	-	-	35	0.9%
Other carcinomas ^h	2,100	5.2%	1,691	5.2%	256	5.2%	132	4.9%	-	-	212	5.4%
Unspecified, "Carcinoma, NOS" (8010,8020-8022)	2,262	5.6%	1,754	5.4%	327	6.7%	157	5.8%	-	-	235	6.0%
Sarcoma and other soft tissue tumors ⁱ	29	0.1%	25	0.1%	-	-	-	-	-	-	-	-
Other specific types ^j	32	0.1%	23	0.1%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	794	2.0%	639	2.0%	90	1.8%	55	2.0%	-	-	93	2.4%
Total	40,676	100.0%	32,746	100.0%	4,887	100.0%	2,687	100.0%	176	100.0%	3,921	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Other adenocarcinoma include histologies 8050,8141-8147,8160-8162,8180-8221,8250-8259,8261-8479,8483-8499,8504-8506,8520-8551,8560,8570-8574,8576,8940-8941.

^g Other specific carcinomas include histologies 8012-8015,8030-8046,8150-8155,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

^h Other carcinomas include histologies 8012-8015,8030-8046,8170-8180,8230-8249,8508,8510-8513,8561-8562,8575,8580-8671.

ⁱ Sarcoma and other soft tissue tumors include histologies 8680-8713,8800-8921,8990-8991,9040-9044,9120-9136,9150-9252,9370-9373,9540-9582.

^j Other specific types include histologies 8720-8790,8930-8936,8950-9030,9060-9110,9260-9365,9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	28,642	93.7%	20,397	94.2%	3,916	90.5%	3,921	94.7%	206	94.9%	4,968	96.2%
Epidermoid carcinoma ^d (8051-8131)	256	0.8%	184	0.8%	49	1.1%	20	0.5%	-	-	25	0.5%
Squamous cell carcinoma (8070-8078,8083-8084)	244	0.8%	176	0.8%	47	1.1%	18	0.4%	-	-	20	0.4%
Adenocarcinoma (8050,8140-8147, 8160-8162,8180-8221, 8250-8507,8514,8520-8551, 8560,8570-8574, 8576,8940-8941)	25,739	84.2%	18,222	84.1%	3,478	80.4%	3,713	89.7%	181	83.4%	4,464	86.4%
Adenocarcinoma, NOS (8140)	14,887	48.7%	10,900	50.3%	2,018	46.6%	1,798	43.4%	91	41.9%	2,195	42.5%
Adenocarcinoma, intestinal type (8144)	2,504	8.2%	1,483	6.8%	368	8.5%	604	14.6%	33	15.2%	446	8.6%
Carcinoma, diffuse type (8145)	1,027	3.4%	648	3.0%	122	2.8%	243	5.9%	-	-	211	4.1%
Linitus plastica (8142)	211	0.7%	161	0.7%	24	0.6%	23	0.6%	-	-	61	1.2%
Mucinous adenocarcinoma (8470-8473,8480,8482)	445	1.5%	314	1.4%	81	1.9%	47	1.1%	-	-	67	1.3%
Mucin-producing adenocarcinoma (8481)	181	0.6%	134	0.6%	32	0.7%	-	-	-	-	23	0.4%
Signet ring adenocarcinoma (8490)	5,224	17.1%	3,718	17.2%	683	15.8%	752	18.2%	38	17.5%	1,231	23.8%
Other adenocarcinomas ^e	1,260	4.1%	864	4.0%	150	3.5%	231	5.6%	-	-	230	4.5%
Other specific carcinomas (8012-8015,8030-8046, 8150-8155,8170-8175, 8230-8249,8508,8510-8513, 8561-8562,8575,8580-8671)	1,867	6.1%	1,445	6.7%	262	6.1%	100	2.4%	-	-	354	6.9%
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	780	2.6%	546	2.5%	127	2.9%	88	2.1%	-	-	125	2.4%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^e Other adenocarcinomas includes histologies 8050, 8141, 8143, 8146-8147, 8160-8162, 8180-8221, 8250-8469, 8474-8479, 8483-8489, 8491-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 24.22 - continued

Cancer of the Stomach (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2001-2005
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Sarcoma and other soft tissue tumors (8680-8713,8800-8921, 8990-8991,9040-9044, 9120-9136,9150-9252, 9370-9373,9540-9582)	71	0.2%	51	0.2%	-	-	-	-	-	-	-	-
Other specific types (8720-8790,8930-8936, 8950-8983,9000-9030, 9060-9110,9260-9365, 9380-9539)	1,707	5.6%	1,108	5.1%	381	8.8%	197	4.8%	-	-	169	3.3%
Unspecified (8000-8005)	147	0.5%	104	0.5%	17	0.4%	19	0.5%	-	-	21	0.4%
Total ^d	30,568	100.0%	21,661	100.0%	4,328	100.0%	4,141	100.0%	217	100.0%	5,166	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^d Total includes carcinoma cases from the previous page.

- Statistic not shown due to fewer than 16 cases during the time period.

Table 26.22

Cancer of the Thyroid (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2006-2010
Both Sexes by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Carcinoma	51,927	99.7%	42,591	99.7%	3,343	99.3%	5,032	99.8%	212	99.5%	7,439	99.7%
Epidermoid carcinoma ^d (8051-8131)	54	0.1%	44	0.1%	-	-	-	-	-	-	-	-
Adenocarcinoma ^e	50,173	96.3%	41,167	96.4%	3,191	94.8%	4,893	97.0%	204	95.8%	7,203	96.6%
Papillary adenocarcinoma (8050,8260,8340-8344, 8350,8450)	45,473	87.3%	37,428	87.6%	2,693	80.0%	4,528	89.8%	184	86.4%	6,685	89.6%
Follicular carcinoma (8330-8332,8335)	3,049	5.9%	2,342	5.5%	362	10.8%	273	5.4%	18	8.5%	346	4.6%
Oxyphilic (8290)	1,313	2.5%	1,131	2.6%	101	3.0%	66	1.3%	-	-	134	1.8%
Other specific carcinomas ^f	937	1.8%	778	1.8%	88	2.6%	45	0.9%	-	-	141	1.9%
Medullary carcinoma (8510)	905	1.7%	752	1.8%	84	2.5%	44	0.9%	-	-	137	1.8%
Carcinoma, NOS (8004,8010-8012, 8020-8022,8030-8032)	763	1.5%	602	1.4%	59	1.8%	90	1.8%	-	-	86	1.2%
Anaplastic carcinoma (8004,8012,8020-8021, 8030-8032)	475	0.9%	381	0.9%	31	0.9%	58	1.1%	-	-	53	0.7%
Sarcoma and other soft tissue tumors ^g	-	-	-	-	-	-	-	-	-	-	-	-
Other specific types ^h	-	-	-	-	-	-	-	-	-	-	-	-
Unspecified (8000-8003,8005)	151	0.3%	115	0.3%	17	0.5%	-	-	-	-	20	0.3%
Total	52,095	100.0%	42,718	100.0%	3,365	100.0%	5,044	100.0%	213	100.0%	7,459	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^f Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^g Other specific carcinomas include histologies 8013-8015, 8033-8046, 8150-8155, 8170-8171, 8230-8249, 8510, 8512, 8561-8562, 8575, 8580-8671.

^h Sarcoma and other soft tissue tumors include histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

ⁱ Other specific types include histologies 8720-8790, 8930-8936, 8950-8983, 9000-9030, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.